The proteasome inhibitor bortezomib (also known as PS-341/ Velcade) is a dipeptidyl boronic acid that has recently been approved for use in patients with multiple myeloma. Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. In this report, oligonucleotide microarray analysis of the 8226 multiple myeloma cell line showed a predominant induction of gene products associated with the endoplasmic reticulum secretory pathway following short-term, high-dose exposure to bortezomib. Examination of mediators of endoplasmic reticulum stress-induced cell death showed specific activation of caspase 12, as well as of caspases 8, 9, 7, and 3, and cleavage of bid. Treatment of myeloma cells with bortezomib also showed disregulation of intracellular Ca 2+ as a mechanism of caspase activation. Cotreatment with a panel of Ca 2+ -modulating agents identified the mitochondrial uniporter as a critical regulatory factor in bortezomib cytotoxicity. The uniporter inhibitors ruthenium red and Ru360 prevented caspase activation and bid cleavage, and almost entirely inhibited bortezomib-induced cell death, but had no effect on any other chemotherapeutic drug examined. Additional Ca 2+ -modulating agents, including 2-amino-ethoxydiphenylborate, 1,2-bis (o-aminophenoxy) ethane-tretraacetic acid (acetoxymethyl) ester, and dantrolene, did not alter bortezomib cytotoxicity. Analysis of intracellular Ca 2+ showed that the ruthenium-containing compounds inhibited Ca 2+ store loading and abrogated the desensitized capacitative calcium influx associated with bortezomib treatment. These data support the hypothesis that intracellular Ca 2+ disregulation is a critical determinant of bortezomib cytotoxicity. (Cancer Res 2005; 65(9): 3828-36) 
Introduction
Bortezomib (PS-341/Velcade) is a dipeptide containing boronic acid, which has been recently approved for therapeutic use in refractory multiple myeloma (1, 2) . Bortezomib forms a covalent bond with the active site threonine in the core of the 20S proteasome and inhibits the chymotryptic activity of the proteasome; however, its exact mechanism of cytotoxicity and selectivity for transformed cells is not known. A large number of proteins that are involved with carcinogenesis are known to be regulated by the ubiquitinproteasome system of degradation, including transcription factors such as activator protein-1 and p53, signal transduction molecules such as Jak2 and cbl, the cell cycle regulators p21 and p27, and regulatory factors such as the nuclear factor-nB inhibitors InBa, h, q, and p100. Many laboratories have investigated these proteins as potential targets of bortezomib-mediated cytotoxicity, and these studies have clearly shown that bortezomib is a potent inhibitor of the 26S proteasome with effects that can be directly related to protein stabilization (3) (4) (5) . However, the molecular switch that initiates cell death in this pathway has not yet been identified.
Over the past 10 years, two primary apoptotic pathways have been described. The ''extrinsic pathway'' is initiated by ligation of cellsurface death receptors such as CD95 (Fas/Apo-1), tumor necrosis factor receptor 1, and death receptors 4 and 5 (see review in ref. 6 ). Upon receptor ligation, the adapter protein Fas-associated death domain protein is recruited, which in turn recruits procaspase 8, resulting in the formation of the death-inducing signaling complex. Death-inducing signaling complex formation is generally thought to initiate apoptosis by induced proximity autocatalytic activation of caspase 8 and subsequent downstream effectors. In contrast, the ''intrinsic pathway'' is associated with various cell damaging agents such as reactive oxygen species and DNA strand breaks, and is initiated by mitochondrial release of cytochrome c, formation of the apoptosome, and activation of procaspase 9. Cross talk between these two pathways occurs through the Bcl-2 family, which includes both proapoptotic and antiapoptotic members (7) . For example, bid is a proapoptotic factor that has been shown to be cleaved by caspase 8, releasing an activated fragment, which can induce mitochondrial release of cytochrome c. Bcl-x L is an antiapoptotic factor that has been shown to inhibit cell death induced by both death receptor ligation and cytotoxic drugs in some cell types (8) . Thus, bid activation by caspase 8 and mitochondrial release of cytochrome c are thought to amplify extrinsic apoptotic signals by recruiting involvement of the mitochondrial pathway.
More recently, a third pathway has been identified that is initiated by the endoplasmic reticulum (ER; see review in ref. 9) . At least two different mechanisms have been associated with ER stress-initiated apoptosis, the unfolded protein response and disregulation of Ca 2+ homeostasis. Disregulation of intracellular Ca 2+ was among the first hallmarks of apoptosis, predating the identification of the caspase cascade as a mechanism of programmed cell death (see review in ref. 10 2+ into the cell and was resistant to apoptosis following B-cell receptor ligation. Transfection of IP3R expression constructs restored this capability; however, the identity of the plasma membrane channel activated by elevated inositol triphosphate and the mechanism of IP3R regulation remain under investigation. Additional studies have also implicated IP3R-mediated CCI as a modulator of apoptosis (12) (13) (14) . Jayaraman et al. showed that transfection of T lymphocytes with IP3R antisense rendered the cells resistant to apoptotic cell death induced by dexamethasone, ionizing radiation, T-cell receptor ligation, and CD95 crosslinking. This resistance could be overcome by pharmacologically increasing cytosolic Ca 2+ , supporting a role for CCI in apoptosis. In addition to their function in metabolism and apoptosis, mitochondria are known to participate in Ca 2+ homeostasis. Excess cytosolic Ca 2+ is taken up into the mitochondria through a lowaffinity inner membrane Ca 2+ uniporter and released back to the cytosol by three independent mechanisms: reversal of the uniporter, Na + /H + -dependent Ca 2+ exchange, or the mitochondrial permeability transition pore opening. Additional studies have shown IP3R-mediated translocation of Ca 2+ to mitochondria following treatment with staurosporine or ceramide, resulting in rapid permeability transition pore opening, cytochrome c release, and activation of downstream mediators of apoptosis (15) . In these studies, apoptosis could be inhibited by ruthenium red, a cationic dye that blocks the mitochondrial uniporter, or by bongkreikic acid, which binds to the adenine nucleotide translocator and prevents permeability transition pore opening. More recently, several studies have shown a role for the Bcl-2 family of apoptotic regulators in the translocation of Ca 2+ from the ER to the mitochondria (16, 17) . Collectively, these studies show an additional mechanism of cross talk between the known apoptotic pathways and emphasize the complex coordination of signals that contribute to cell survival or death.
In the present study, we have examined the early events associated with bortezomib-induced cell death of multiple myeloma cells. Multiple myeloma is a malignancy of secretory plasma cells, and as such, they contain a highly developed ER, characteristic of secretory cells. We show that bortezomib treatment induces the expression of proteins associated with the ER secretory pathway, activation of caspase 12, and disregulation of Ca 2+ homeostasis leading to cell death. We further show that inhibition of mitochondrial Ca 2+ uptake by ruthenium compounds completely abrogates the cytotoxic activity of bortezomib, whereas a series of Ca 2+ -modulating agents has no significant effect. These results suggest that bortezomib initiates apoptosis in myeloma cells by a unique mechanism that is not known to be activated by any other chemotherapeutic agent. Oligonucleotide expression analysis. 8226 myeloma cells were exposed to 50 nmol/L bortezomib for 4 hours and harvested for isolation of RNA using the Qiagen Rneasy protocol followed by Oligotex mRNA kit (Qiagen, Valencia, CA). Three independent experiments were done on consecutive days, and equal quantities of RNA from each experiment were combined for oligonucleotide microarray analysis using the Affymetrix U113A gene chip, which includes oligonucleotides representative of 22,000 gene products. Data were analyzed using GeneChip software as previously described (19) . Untreated cells were designated as the baseline and comparison metrics calculated to identify differences between the baseline and the cells treated with bortezomib.
Materials and Methods
Cytotoxicity assays. Cytotoxicity analysis was done either by Annexin V-FITC/Mito Tracker red (CMXRos, Molecular Probes, Eugene, OR) staining and flow cytometry or by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay as previously described (20) . For all studies using combinations of a Ca 2+ inhibitor plus cytotoxic agent, the inhibitor was added to the total cell population before plating. Cytotoxic activity of the Ca 2+ -modulating agents alone was determined in preliminary control experiments, and all subsequent assays were done at minimally toxic doses as follows: 2-amino-ethoxydiphenylborate (2-APB), 5 Amol/L; 1,2-bis (o-aminophenoxy) ethane-tretraacetic acid (acetoxymethyl) ester (BAPTA-AM), 10 Amol/L; dantrolene, 10 Amol/L; Ru360, 1.0 Amol/L; and ruthenium red, 0.1 Amol/L. All reagents were obtained from Calbiochem (San Diego, CA) with the exception of ruthenium red, which was obtained from Sigma (St. Louis, MO). Bortezomib (PS-341/Velcade) was kindly provided by Millennium Pharmaceuticals (Cambridge, MA).
Immunoblot analysis. Immunoblotting was done as previously described (19) . Briefly, after drug treatment, cells were pelleted by centrifugation, washed once with ice-cold PBS, and lysed in 30 mmol/L HEPES (pH 7.5), 10 mmol/L NaCl, 5 mmol/L MgCl 2 , 25 mmol/L NaF, 1 mmol/L EGTA, 1% Triton X-100, 10% glycerol with 2 mmol/L NaVO 4 , 10 Ag/mL aprotinin, 10 Ag/mL soybean trypsin inhibitor, 25 Ag/mL leupeptin, and 2 mmol/L phenylmethylsulfonyl fluoride for 20 minutes on ice. Lysates were cleared by centrifugation and protein was quantitated by bicinchoninic acid assay (Pierce, Rockford, IL). Equal amounts of protein (30-50 Ag) were separated by SDS-PAGE electrophoresis, transferred to polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA), probed with the specified antibody, and developed using Pierce Supersignal chemiluminescence substrate.
[ The coverslips were then rinsed in HBSS for 20 minutes at 37jC to allow full hydrolysis of the Fura-AM to free acid. The coverslip with the dye-loaded cells was then placed in a 37jC imaging chamber, which is mounted on the stage of an inverted Olympus IX70 microscope (Melville, NY). Light emitted from a 100-W Hg bulb was passed alternately through 340-and 380-nm filters using a filter wheel. The emitted fluorescence was collected using a 40Â 1.35 numerical aperture UV-fluor objective then selected using a 10-nm bandpass filter centered at 510 nm and passed to a CCD camera (Photometrics CH-250, Tucson, AZ). The ratio of the light intensity monitored at 340/380 is used as an index for [Ca 2+ ] i . Specific calibration procedures have been previously reported in detail (21) . A minimum of 5 cells was analyzed in each experimental condition, and all experiments were repeated at least thrice. In the standard protocol, Ca 2+ was removed from the media for 2 minutes before addition of cyclopiazoic acid, then after 7 minutes Ca 2+ was added back to analyze the magnitude of CCI. The peak changes in Ca 2+ following cyclopiazoic acid and Ca 2+ addition were calculated as percent change from the zero Ca 2+ baseline (baseline) using the formula [(R peak following treatment) À (R immediately before treatment)] / (R peak immediately before treatment), where R is the 340/ 380 ratio. Rate of rise was calculated as [(R peak ) À (R baseline )] / (time at R peak À time at R baseline ). Significance was determined using the Student's twosided t test.
Results
Bortezomib treatment induces the expression of gene products associated with the endoplasmic reticulum secretory pathway. To investigate the mechanism of bortezomib-mediated cell death, oligonucleotide microarray analysis was used to examine the differential gene expression profile of the 8226 myeloma cell line following exposure to bortezomib. These studies were designed to examine the acute response of myeloma cells to bortezomib. Therefore, myeloma cells were treated with a short-term (4-hour) exposure using a dose corresponding to the approximate IC 70 for a 24-hour exposure as determined by MTT and Annexin V-FITC. No phenotypic indications of cell death are visible at this time point. Using untreated cells as baseline, 25 gene products were identified as significantly expressed ( fluorescence signal >200) and increased by >2-fold in cells maintained in suspension, whereas only 8 were decreased at the level of RNA expression. The most consistent and dramatic increase occurred in gene products associated with the ER secretory pathway (Table 1) . Specifically, two isoforms of the chaperone 70 kDa heat shock protein (hsp70), 1A and 1B, were induced by 2.6-and 2.9-fold, respectively. The hsp70-interacting protein, BCL2-associated athanogene 3, was similarly induced 2.0-fold, and the luminal ER Ca 2+ -regulating protein, calreticulin, was induced by 2.0-fold. Protein expression of these gene products was confirmed by Western blot analysis (data not shown).
Caspase 12 is activated by bortezomib treatment. One of the mechanisms proposed to contribute to ER stress-mediated death is the activation of the ER-resident caspase 12 (22) . Caspase 12 is localized on the cytoplasmic side of the ER. It has been shown to be proteolytically activated by agents that induce ER stress, including tunicamycin, thapsigargin, brefeldin A (23), and m-calpain (24) . Manganese(II) (25) , h-amyloid protein, and disruption of Ca 2+ homeostasis (24) are also reported to activate caspase 12. Examination of caspase 12 activation in 8226 myeloma cells following drug treatment with a variety of cytotoxic agents showed that bortezomib activates caspase 12 in myeloma cells, whereas other cytotoxic agents, including doxorubicin, melphalan, and CD95 ligation, did not (Fig. 1) . This is not due to absence of druginduced cytotoxicity, as analysis of apoptosis by Annexin V-FITC and flow cytometry showed comparable cell death in all drugtreated samples (data not shown). Additionally, examination of additional caspase cleavage products identified the predicted cleavage of caspase 9 in all experimental conditions, caspase 8 by CD95 cross-linking, and caspases 7 and 3 by all cytotoxic agents. Interestingly, caspase 8 was also cleaved by bortezomib treatment, demonstrating the involvement of apoptotic mediators typically associated with the extrinsic pathway.
Caspase 8 modulates the activation of caspase 12. Caspase activation has been shown to occur in a relatively linear sequence, and specific tetrapeptide inhibitors can be used to determine hierarchical ordering. To identify the apical caspase in bortezomib-mediated cytotoxicity, 8226 myeloma cells were treated with 50 nmol/L bortezomib in the presence and absence of the caspase 3 inhibitor DEVD, the caspase 8 inhibitor IETD, or the pan caspase inhibitor Z-VAD. All reagents were FMK conjugated for cell permeability, and Z-FA-FMK was used as a negative control. As shown in Fig. 2 , 50 nmol/L bortezomibinduced activation of caspases 12, 3, 8, and 9, and was not inhibited by FA-FMK. The caspase 3 inhibitor DEVD partially prevented the cleavage of caspase 3, but had no effect on caspase 12, 8, or 9, and only slightly inhibited cell death. In contrast, the caspase 8 inhibitor IETD reduced the cleavage of contributes to bortezomib-mediated cytotoxicity, drug activity was examined in the presence of a series of Ca 2+ -interacting agents. These studies were based on the hypothesis that if disregulation of intracellular Ca 2+ is required for bortezomib-mediated cell death, then inhibition of intracellular Ca 2+ homeostasis using a panel of pharmacologic inhibitors would alter the response of myeloma cells to bortezomib-induced cell death. Calcium release from the ER is regulated by two primary receptors, the IP3R and the ryanodine receptor. The ryanodine receptor can be inhibited by dantrolene, which is used clinically as a muscle relaxant to block Ca 2+ release from the sarcoendoplasmic reticulum. 2-APB was originally described as an IP3R inhibitor (26) , although more recent data have shown that 2-APB is also a potent blocker of capacitative Ca 2+ entry channels independent of its inhibition of the IP3R (27, 28 via the mitochondrial uniporter can be inhibited by ruthenium red (29) or its dinuclear analog, Ru360 (30) . Preliminary experiments showed that neither ruthenium red nor Ru360 induced significant cell death at concentrations up to 100 Amol/L (data not shown). All other inhibitors were used at doses that resulted in less than 15% cell death in control experiments. 8226 myeloma cells were simultaneously exposed to bortezomib in the presence or absence of minimally toxic doses of each Ca 2+ -interacting agent, and cytotoxicity was analyzed by MTT dye reduction. As shown in Fig. 3A , cotreatment of 8226 cells with the mitochondrial Ca 2+ uptake inhibitor ruthenium red (0.1 Amol/L) or Ru360 (1.0 Amol/L) almost entirely abrogated bortezomib-induced cytotoxicity. Identical results were obtained for additional cell lines, including the myeloma cells H929, U266, and MM.1S, diffuse large cell lymphoma cells DB and Raji, and the mantle cell lymphoma cell line Granta-1 (data not shown). No significant inhibition of bortezomib-mediated cytotoxicity was seen in cells cotreated with agents that inhibit Ca 2+ efflux from the ER or with the Ca 2+ chelator BAPTA-AM (Fig. 3B) . Increasing concentrations of 2-APB up to 100 Amol/L did not produce any additional activity, nor did dantrolene at concentrations up to 50 Amol/L (data not shown). However, preliminary control experiments showed that BAPTA-AM is significantly toxic to myeloma cells, with 30% apoptosis at 5 Amol/L, and it is possible that the concentration used for these experiments may not have been sufficient to entirely deplete cytosolic Ca 2+ . To rule out the possibility that ruthenium red and Ru360 were affecting the activity of mitochondrial succinate dehydrogenase, which is required for MTT dye reduction, apoptosis was verified by Annexin V-FITC staining and flow cytometry analysis. Identical results were obtained (data not shown). Additionally, 4-day MTT analysis shows that myeloma cells treated with bortezomib in the presence of ruthenium-containing agents continue to proliferate, suggesting that inhibition of the mitochondrial uniporter does not only delay apoptosis but prevents cell death.
To determine if the mitochondrial uniporter is involved in cell death induced by standard chemotherapeutic drugs, myeloma cells were treated with a variety of cytotoxic agents representing diverse mechanisms of activity in the presence and absence of 0.1 Amol/L ruthenium red. Cotreatment with ruthenium red has no effect on the cytotoxic activity of the topoisomerase II inhibitors doxorubicin and mitoxantrone, alkylating agents melphalan and cisplatinum, or the mitochondrial targeting agents imexon (31) and dexamethasone (data not shown). Additionally, the cytotoxic effect of thapsigargin, which is an irreversible inhibitor of the smooth ER Ca 2+ -ATPase and induces Ca 2+ store depletion, is not inhibited by ruthenium red (Fig. 3B) . These data show the dramatic specificity of the inhibitory effects of ruthenium-containing agents on bortezomib-induced death and suggest that the critical determinant of bortezomib cytotoxicity is the mitochondrial-dependent disregulation of Ca 2+ .
Mitochondrial Ca
2+ + disregulation occurs upstream of caspase activation. To determine if mitochondrial Ca 2+ disregulation was required to initiate caspase activation or, conversely, if caspase activity was required for Ca 2+ disregulation, caspase activity was examined in the presence of the Ca 2+ -modulating agents. 8226 myeloma cells were cotreated with 50 nmol/L PS-341 in the presence or absence of 2-APB, BAPTA-AM, or ruthenium red and examined for caspase activation. Similar to Fig. 1 , bortezomib alone induces significant caspase activation (Fig. 4) . Inhibition of the mitochondrial Ca 2+ uniporter with 0.1 Amol/L ruthenium red entirely prevented activation of caspases 12, 8, and 3 and cleavage of bid. Cotreatment with 1.0 Amol/L Ru360 gave identical results (data not shown). In contrast, 2-APB and BAPTA-AM had no effect. These data further support the hypothesis that mitochondrial Ca 2+ is the critical determinant of bortezomib-mediated cytotoxicity. Furthermore, mitochondrial Ca 2+ disregulation occurs before caspase activation, including caspase 8, which is typically considered upstream of mitochondrial permeability transition. Ca 2+ + homeostasis is disregulated following bortezomib treatment. To identify the effectors of Ca 2+ homeostasis that may be contributing to bortezomib-mediated cytotoxicity, imaging of cytosolic Ca 2+ was done using the ratiometric dye Fura-AM. Initial , which quickly recovers to basal levels (Fig. 5A) . Cytosolic Ca 2+ peaked within 5 to 8 minutes of treatment, with complete recovery to baseline occurring by 15 minutes in all cells analyzed. This transient increase in [Ca 2+ ] i following bortezomib treatment may be due to release of Ca 2+ from intracellular stores and/or influx from the extracellular space. Subsequent addition of cyclopiazoic acid, to induce store unloading, elicited another large transient increase in [Ca 2+ ] i , indicating that significant levels of Ca 2+ remained within the stores following bortezomib exposure (Fig. 5A) .
To investigate the potential mechanism for the bortezomib effects on [Ca 2+ ] i , 8226 cells were incubated with 500 nmol/L PS-341 for 2 hours before analysis of [Ca 2+ ] i . At this time following bortezomib treatment, mitochondrial membrane potential remains intact, as determined by control experiments using the mitochondrial dye CMXRos as well as by Western blotting for cytochrome c release (data not shown). A standard cyclopiazoic acid response protocol was used to determine if store Ca 2+ was altered following bortezomib treatment. ] i was analyzed. As shown in Fig. 5B (t = 11-14 min) and Fig. 6B and C, both the magnitude and rate of CCI increased in bortezomib-treated cells compared with controls (Fig. 6C) , suggesting that bortezomib alters either the number of store-operated Ca 2+ channels or the length of time such channels remain open following store depletion.
The effect of inhibiting the mitochondrial Ca 2+ uniporter on the [Ca 2+ ] i responses to cyclopiazoic acid and the subsequent CCI were evaluated by incubating cells with ruthenium-containing compounds before analysis of [Ca 2+ ] i responses. Incubation of cells with Ru360 in the presence of Ca 2+ efflux inhibitors significantly blunted the cyclopiazoic acid response in both control and bortezomib-treated cells, suggesting a role for mitochondria in regulating the efflux from or loading of Ca 2+ into the ER (Fig. 6 ).
Ru360 also significantly and substantially decreased the rate and magnitude of CCI in both untreated controls and bortezomibtreated cells (Fig. 6) . Moreover, the peak [Ca 2+ ] i attained in cells treated with bortezomib in the presence of Ru360 was significantly less than that seen with bortezomib alone (Fig. 6B) 
Discussion
The boronic acid dipeptide bortezomib is a small molecule inhibitor of the 20S proteasome that has shown antitumor activity in a number of cell types, and is particularly effective in the treatment of patients with multiple myeloma. The findings presented here show a unique apoptotic pathway initiated by bortezomib that uses Ca 2+ to activate both intrinsic and extrinsic mediators.
The ubiquitin-proteasome system of protein degradation plays an essential role in quality control of newly synthesized proteins. The data presented here show that bortezomib induces the expression of proteins associated with the ER secretory pathway, indicating a potential ER stress-initiated pathway to apoptosis. While these studies were in progress, two additional studies reported gene expression profiling in cells treated with proteasome inhibitors. Fleming et al. (32) examined the profile of Saccharomyces cerevisiae treated with bortezomib or hlactone, whereas Mitsiades et al. (33) reported the profile of the human multiple myeloma cell line MM.1S following exposure to 100 nmol/L bortezomib. These data are highly compatible; as in all three studies, the most significant and dramatic induction is that of proteins associated with the ER secretory pathway, suggesting that the mechanism of bortezomib cytotoxicity involves ER stress.
As with many cellular stress responses, if the level of stress exceeds the adaptive capacity of the cell, an apoptotic pathway is initiated. ER stress-mediated apoptosis has been associated with the activation of caspase 12 (23, 34, 35) , although the existence of caspase 12 in humans is somewhat controversial. Caspase 12 was originally identified in a murine system, and Fischer et. al. (36) reported a human caspase 12 sequence that is predicted to encode multiple splice variants and stop codons. Antibodies directed against a conserved region of the mouse protein identify a human cellular protein that is of similar relative molecular mass with appropriately sized cleavage fragments (23, 34) . In our system, we cannot rule out the possibility that this anti-caspase 12 antibody may cross-react with another as yet unidentified caspase, however, the activation of this caspase is clearly restricted to ER stress-initiated apoptosis. Several mechanisms of caspase 12 activation have been identified, and would seem to be cell type specific (37) . The present study shows that bortezomib-mediated activation of caspase 12 may be modulated by caspase 8, but is dependent on mitochondrial Ca 2+ disregulation. Our findings also show mitochondrial Ca 2+ influx as an event upstream of caspase activation and bid cleavage. Inhibition of the mitochondrial uniporter with ruthenium-containing compounds entirely abrogated bortezomib-induced caspase activation. In contrast, Darios et al. (38) showed that mitochondrial Ca 2+ uptake is a consequence of these events in a model system of ceramide-mediated apoptosis in neuronally differentiated PC12 cells. Additionally, in this study, they were unable to inhibit ceramide-induced cell death with ruthenium-containing compounds, suggesting that the mechanism of Ca 2+ disregulation incurred by ceramide is distinct from the cellular response to proteasome inhibition.
The regulation of Ca 2+ signaling and Ca
2+
-dependent proteins has long been associated with apoptosis, but only recently have their roles been defined and the regulatory mechanisms begun to be identified. The regulation of apoptosis by Ca 2+ signaling was first shown with the identification of a Ca 2+ /Mg 2+ -dependent endonuclease responsible for the DNA fragmentation, which is often considered the hallmark of apoptosis (39) . Increased cytosolic Ca 2+ concentration has been found to subsequently activate Ca 2+ -dependent enzymes that modulate cell death, including A-calpain and calcineurin (40) . Furthermore, Ca 2+ influx into mitochondria, if substantial, can activate cytochrome c release, which subsequently activates caspase activity (15) . The lumen of the ER is the primary storage location for Ca 2+ , where it is either free or bound to luminal proteins such as calreticulin, an unfolded protein-responsive chaperone that we found to be induced by 2-fold following bortezomib treatment. In this respect, Arnaudeau et al. (41) showed that increased expression of calreticulin resulted in an increased rate of agonist-induced Ca 2+ release and reduced mitochondrial Ca 2+ retention. Although a functional role for calreticulin in bortezomib-mediated cell death has not yet been defined, the observed elevation of mRNA and protein levels suggests that calreticulin expression may be induced as a cellular response to ER stress, and therefore alterations in ER Ca 2+ storage or release may play a role in the observed disregulation of Ca 2+ homeostasis. However, the data shown in Figs. 5 and 6 clearly show that releasable store Ca 2+ levels are not substantially different in cells treated with bortezomib. The primary difference in Ca 2+ homeostasis observed in bortezomib-treated cells was a significant elevation in cyclopiazoic acid-activated CCI (Figs. 5 and 6 ), indicating an increased potential for Ca 2+ influx following store release. Interestingly, inhibition of mitochondrial Ca 2+ uptake by ruthenium red significantly reduced ER Ca 2+ loading and the bortezomib enhancement of store-activated influx. The mechanism by which depletion of ER Ca 2+ activates plasma membrane channels is unclear; however, one model suggests that mitochondria play an important role in regulating both the loading state of Ca 2+ stores (42) and the coupling of store Ca 2+ released for channel activation (43) . We propose a model where bortezomib evokes a transient release of Ca 2+ stores leading to mitochondrial Ca 2+ influx. Mitochondrial Ca 2+ sensors associated with the uniporter initiate CCI, which is enhanced in bortezomib-treated cells (Fig. 6 ), leading to caspase activation. Ruthenium compounds would then be protective by blocking mitochondrial loading and CCI activation and the Ca 2+ -dependent signal transduction pathways that initiate cell death (44) . The identity of the signal pathways involved in this regulation remains under intense investigation. Further definition of the mediators in this pathway will promote the design of strategies to enhance drug activity, reduce toxicity, and overcome drug resistance.
